We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App





Cellink Relaunches Real-Time qPCR Instrument for COVID-19

By LabMedica International staff writers
Posted on 04 Apr 2020
CELLINK (Boston, MA, USA) has begun reselling its qPCR instrument which can be used for the quantification and genotyping of human viral pathogens, such as SARS-CoV-2. More...
CELLINK is offering the instrument at a low-cost point to help advance research related to the COVID-19 pandemic and provide scientists with the tools they need to make a difference.

CELLINK is a niche life-science company that develops and delivers life-science solutions for cell culturing. It focuses on three application areas, including bioprinting, analysis and liquid handling & bioprocessing to deliver a complete solution in its life science niche. The company targets to develop and commercialize cell culture technologies, enabling researchers to print human organs and tissues for pharmaceutical and cosmetic applications.

CELLINK’s qPCR instrument for the quantification and genotyping of human viral pathogens, such as SARS-CoV-2, uses a laboratory technique of molecular biology based on the polymerase chain reaction. It monitors the amplification of a targeted DNA molecule during the PCR (i.e., in real time). The instrument includes dual channels and is open source, allowing users to use any kit to run their samples. It is designed as a high-quality, low-throughput qPCR cycler. The instrument is easy to use and runs a sample in 20-40 minutes.

Related Links:
CELLINK


Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Online QC Software
Acusera 24•7
Hematology Consumables
Bioblood Devices
Electrolyte Analyzer
CBS-4000 (CBS-400)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image Credit: Shutterstock

New Biomarkers Predict Resistance to Targeted Therapy in Rare Blood Cancer

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive leukemia with limited treatment options and a poor prognosis. Although tagraxofusp is the first approved targeted therapy for... Read more

Immunology

view channel
Image:Proteomic tear-fluid analysis revealed abnormal patterns in proteins that regulate nerves and T cells in individuals with eye problems (Image Credit: Adobe Stock)

Diagnostic Models Detect Hidden Eye Abnormalities After Mild COVID-19

Persistent ocular symptoms after COVID-19 can severely affect reading, work, and daily tasks, yet standard eye exams often reveal no clear abnormalities. Patients experiencing photophobia, eye pain, and... Read more

Industry

view channel
Photo courtesy of Natera

Natera’s Signatera Earns IVDR Certification for Solid Tumor MRD Testing

Natera’s Signatera has received certification as a Class C device under the European Union’s In Vitro Diagnostic Regulation (IVDR), becoming the first personalized MRD test for solid tumors to achieve... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.